Altimmune, Inc. (ALT)

Altimmune, Inc.'s stock price has experienced significant fluctuations over the past six months. As of November 26, 2025, the share price was $5.18, a 40.72% decline from the previous year. The stock decreased by 40.78% over the last 12 months, with a year-to-date return of -28.29%. However, there has been a recent positive trend, with the stock increasing by 27.34% in the past month and 13.88% compared to the previous week. Analyst ratings have been positive, with several firms reiterating "Buy" recommendations. The company presented AI-based analysis of liver fibrosis reduction data from its Phase 2B trial of pemvidutide in MASH in November 2025. Altimmune, Inc. was dropped from the Russell 3000E Value Index and Russell Microcap Value Index in June 2025.

As a clinical-stage biopharmaceutical company, Altimmune, Inc. does not have commercialized products with traditional demand seasonality. There is observed seasonality in the implied volatility of Altimmune's stock options, which historically tends to rise most in March and decline to its lowest levels in September. This relates to market sentiment and trading activity rather than product demand.

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for obesity, metabolic, and liver diseases. Their lead product, pemvidutide, is in Phase 3 trials for obesity and MASH. The company is also developing HepTcell for chronic hepatitis B. Altimmune was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Altimmune, Inc. is headquartered in Gaithersburg, Maryland, United States. The available information primarily details its corporate location and does not specify a broader international geographic operational footprint or market reach for its clinical-stage products.

Altimmune, Inc.'s brand reputation is largely tied to the progress of pemvidutide. The company has strong analyst support, with a "Strong Buy" consensus rating. Positive data from the Phase 2B trial of pemvidutide in MASH contributes to a favorable scientific and investment outlook. There is no readily available information suggesting specific negative events that have broadly impacted Altimmune's brand reputation in the past year, beyond the inherent volatility and risks associated with clinical-stage biotechnology companies.

Altimmune, Inc.'s ownership is a mix of individual and institutional investors. Individual investors hold approximately 49% to 59% of the company's shares, and institutional investors hold 35% to 56%. As of November 2025, nearly 75% of outstanding shares were held by institutions. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. The Vanguard Group, Inc. is the largest shareholder with 6.1% of shares outstanding, followed by BlackRock, Inc. with 6.1% and State Street Global Advisors, Inc. with 3.5%.